Mithra FY23: better than expected operations, but cash and liabilities dominate
Mithra's FY23 results reveal € 40m revenues and € -48m REBITDA somewhat higher than our expectations, although a € 74m impairment on the CMO and Zoreline tanks the net loss to € 173.5m. While the monetisation process for (parts of) the business is ongoing, we estimate that little value could be left for shareholders. We therefore adopt a Sell rating (previously Reduce) and decrease our TP from € 1.0 to € 0.1.Mithra Pharmaceuticals SA is a Belgium-based company active in the pharmaceutical industry. The Company is dedicated to provide products and services for the fertility, contraception and menopause of women. It has a number of patent families regarding Estetrol (E4), a natural estrogen produced by the human foetus, which enables the investigation of fertility and contraception products. Mithra is focused on the development of two late-stage E4-based products: Estelle, a 5th generation oral contraceptive, and Donesta, a hormone therapy for Vasomotor Symptoms in menopause. Mithra develops a contraceptive vaginal ring called Myring and Zoreline, a biodegradable subcutaneous implant for hormone dependant cancer.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.